Follows adults with lymphoma in France to study outcomes over time
Collects real-life health information from adults with several types of lymphoma in France.
Plain-language title generated from the registry record
Registry title: REal World Data in LYmphoma and Survival in Adults
Key facts
- Where
- Arras, Besançon, Bordeaux, Bourgoin, Caen, Chambéry, Clermont-Ferrand, Créteil, Dijon, Dunkirk, Grenoble, La Roche-sur-Yon, La Tronche, Le Mans, Libourne, Lille, Limoges, Lyon, Montpellier, Mulhouse, Nantes, Niort, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Roubaix, Rouen, Saint-Brieuc, Saint-Cloud, Saint-Priest-en-Jarez, Strasbourg, Toulouse, and Vannes, FranceSee the 37 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with one of 7 types of lymphoma, before they have had lymphoma treatment. It follows them over time.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Lymphoma diagnosed in the last 6 months (180 days). Types: diffuse large B-cell, follicular, mantle cell, marginal zone, T-cell, Hodgkin's, or Burkitt lymphoma.
- Earlier treatment
- Must not have had anti-lymphoma treatment already, except a pre-phase (typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination).
Main reasons for not taking part
- Documented HIV infection
- Anti-lymphoma treatment already received (except pre-phase)
- Other lymphoma types, such as chronic lymphocytic leukemia, Waldenström macroglobulinemia, mycosis fungoides or Sézary syndrome
- Primary DLBCL of the central nervous system
- Post-transplant lymphoproliferative disorders (PTLD)
Read by machine on 12 November 2026.
Where in France
- Unité d'Hématologie Clinique, CH D'ARRASArras, FranceContact: Pauline LIONNE-HUYGHE, MDTaking people
- Service d'Hématologie, CHU Jean MinjozBesançon, FranceContact: Adrien CHAUCHET, MDTaking people
- Institut BergonieBordeaux, FranceContact: Fontanet BIJOU, MDTaking people
- Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord AquitaineBordeaux, FranceContact: Olivier FITOUSSI, MDTaking people
- Centre Hospitalier Pierre OudotBourgoin, FranceContact: Florence LACHENAL, MDTaking people
- Service d'Hématologie, Institut d'Hématologie de Basse NormandieCaen, FranceContact: Gandhi DAMAJ, PhDTaking people
- METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,Chambéry, FranceContact: Gian Matteo PICA, MDTaking people
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-FerrandClermont-Ferrand, FranceContact: Romain GUIEZE, PhDTaking people
- Unité Hémopathies Lymphoïdes, Hôpital Henri MondorCréteil, FranceContact: Corinne HAIOUN, PhDTaking people
- CHU François MitterrandDijon, FranceContact: René-Olivier CASASNOVAS, MDTaking people
- Service Hématologie, Centre Hospitalier de DunkerqueDunkirk, FranceContact: Christophe FRUCHART, MDTaking people
- Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,Grenoble, FranceContact: Cécile LEYRONNAS, MDTaking people
- CHD VendéeLa Roche-sur-Yon, FranceContact: Nadine MORINEAU, MDTaking people
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire MichallonLa Tronche, FranceContact: Rémy GRESSIN, MDTaking people
- Clinique Victor HugoLe Mans, FranceContact: Katell LE DÛ, MDTaking people
- Centre hospitalier LibourneLibourne, FranceContact: Gaelle LABOURE, MDTaking people
- Service des maladies du sang, Hôpital Claude Huriez, CHRU de LilleLille, FranceContact: Franck MORSCHHAUSER, MDTaking people
- Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAULLille, FranceContact: Sandy AMORIM, MDTaking people
- Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,Limoges, FranceContact: Julie ABRAHAM, MDTaking people
- Département d'Hématologie et Oncologie, Centre Léon BérardLyon, FranceContact: Laure LEBRAS, MDTaking people
- Département d'Hématologie Clinique, Hôpital Saint-Eloi,Montpellier, FranceContact: Guillaume CARTRON, PhDTaking people
- Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,Mulhouse, FranceContact: Bernard DRENOU, MDTaking people
- Service d'Hématologie clinique, Centre Hospitalier Universitaire de NantesNantes, FranceContact: Thomas GASTINNE, PhDTaking people
- Centre Hospitalier de NiortNiort, FranceContact: Gaëlle Olivier, MDTaking people
- Service Hématologie, Hôpital St LouisParis, FranceContact: Catherine THIEBLEMONT, PhDTaking people
- CHU Haut LevequePessac, FranceContact: Kamal-Krimo BOUABDALLAH, MDTaking people
- Centre Hospitalier Lyon-SudPierre-Bénite, FranceContact: Hervé Ghesquières, MDTaking people
- Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de PoitiersPoitiers, FranceContact: Stéphanie GUIDEZ, MDTaking people
- Hématologie Clinique, CHU PONTCHAILLOURennes, FranceContact: Thierry LAMY DE LA CHAPELLE, PhDTaking people
- Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor ProvoRoubaix, FranceContact: Laurence DETOURMIGNIES, MDTaking people
- Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUERELRouen, FranceContact: Fabrice JARDIN, PhDTaking people
- Service Hématologie, CH YVES LE FOLLSaint-Brieuc, FranceContact: Vincent LAUNAY, MDTaking people
- Service Hématologie, Institut Curie - Hôpital René HUGUENINSaint-Cloud, FranceContact: Carole SOUSSAIN, MDTaking people
- Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien NeuwirthSaint-Priest-en-Jarez, FranceContact: Ludovic FOUILLET, MDTaking people
- Hopitaux Universitaires de StrasbourgStrasbourg, FranceContact: Luc-Matthieu FORNECKER, MDTaking people
- Institut universitaire du cancerToulouse, FranceContact: Loïc YSEBAERT, MDTaking people
- Hématologie Clinique, CH DE BRETAGNE ATLANTIQUEVannes, FranceContact: Antoine BONNET, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT03869619
- Record updated
- 28 June 2021
- Original description
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.Read full original descriptionShow less
REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.
REALYSA is a platform perfectly set up to
* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions
Inclusion: Signature of the consent form for participation in the REALYSA cohort; Aged over 18 at the time of inclusion; Diagnosed with lymphoma in the last 6 months (180 days); Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma.
Exclusion: Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination); Documented HIV infection; Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:; Chronic lymphocytic leukemia/small lymphocytic lymphoma; Hairy cell leukemia and variant; Lymphoplasmacytic lymphoma; Waldenström macroglobulinemia; Primary DLBCL of the central nervous system (CNS); T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK cells; Mycosis fungoides; Sézary syndrome; Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists); Post-transplant lymphoproliferative disorders (PTLD).